The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.80
Bid: 9.35
Ask: 9.75
Change: 0.20 (2.08%)
Spread: 0.40 (4.278%)
Open: 10.20
High: 10.40
Low: 9.80
Prev. Close: 9.60
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Feb 2022 11:47

RNS Number : 8892B
e-Therapeutics plc
16 February 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B2823H99

Issuer Name

E-THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.000000

< 3%

Position of previous notification (if applicable)

0.000000

4.005700

4.005700

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Sub Total 8.A

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

5168858

1.004500

Sub Total 8.B1

5168858

1.004500%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAFAKFLSAEFA
Date   Source Headline
10th Apr 20247:00 amRNSProposed Fundraise of £28.9m and Cancellation
31st Jan 20244:30 pmRNSTotal Voting Rights
24th Jan 202410:04 amRNSExercise of Options and Issue of Equity
16th Jan 20247:00 amRNSBusiness Update
9th Jan 20244:04 pmRNSDirector Dealing and Issue of Equity
27th Dec 20237:00 amRNSUpdate on OTCQX Market Listing
13th Nov 20239:05 amEQSEdison issues update on e-therapeutics (ETX): More to come in RNAi therapy discovery
2nd Nov 20237:00 amRNSStrategic RWE collaboration with Arcturis
26th Oct 20237:38 amRNSInterim results for the six months to 31 July 2023
19th Oct 20239:54 amRNSNotice of Interim Results
20th Sep 20237:00 amRNSSenior Management Update
7th Sep 202311:47 amRNSExercise of Options and Issue of Equity
31st Jul 20234:30 pmRNSTotal Voting Rights
18th Jul 20234:20 pmRNSResult of Annual General Meeting
6th Jul 20235:27 pmRNSDirector Dealing and Issue of Equity
30th Jun 20237:00 amRNSInvestor Presentation
26th Jun 20237:00 amRNSNotice of Investor Presentation
11th May 20237:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20237:00 amRNSFinal results for the year ended 31 January 2023
28th Apr 20234:30 pmRNSTotal Voting Rights
27th Apr 20237:00 amRNSNotification of Full Year Results Date
28th Mar 20233:57 pmRNSExercise of Options and Issue of Equity
21st Feb 20234:35 pmRNSPrice Monitoring Extension
20th Feb 202310:19 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSFiling of four patent applications
31st Jan 20237:00 amRNSTotal Voting Rights
4th Jan 20233:15 pmRNSDirector Dealing and Issue of Equity
29th Dec 20224:40 pmRNSSecond Price Monitoring Extn
29th Dec 20224:35 pmRNSPrice Monitoring Extension
20th Dec 20224:35 pmRNSPrice Monitoring Extension
31st Oct 20227:00 amRNSTotal Voting Rights
12th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 202210:42 amRNSHolding(s) in Company
10th Oct 20228:03 amRNSHolding(s) in Company
30th Sep 20227:00 amRNSInterim results for the six months to 31 July 2022
30th Sep 20227:00 amRNSFundraise of £13.5 million by way of Subscription
26th Sep 20224:40 pmRNSSecond Price Monitoring Extn
26th Sep 20224:36 pmRNSPrice Monitoring Extension
1st Aug 20227:00 amRNSFiling of eight patent applications
29th Jul 20227:00 amRNSTotal Voting Rights
20th Jul 202210:39 amRNSResult of Annual General Meeting
6th Jul 20227:00 amRNSNotice to Shareholders - AGM Virtual Access
5th Jul 20227:00 amRNSDirector Dealing and Issue of Equity
17th May 20227:00 amRNSNotice of AGM and Posting of Annual Report
4th May 20227:00 amRNSFinal results for the year ended 31 January 2022
27th Apr 20227:00 amRNSNotification of Full Year Results Date
12th Apr 20227:00 amRNSKey Milestone Achieved on Galapagos Collaboration
5th Apr 20227:00 amRNSImmuno-Oncology Research Collaboration with iTeos
16th Feb 20224:41 pmRNSHolding(s) in Company
16th Feb 202211:47 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.